论文部分内容阅读
目的研究非小细胞肺癌对新辅助化疗敏感度的差异。方法应用免疫组化方法检测经新辅助化疗组与未经新辅助化疗组不同分化程度和不同病理类型非小细胞肺癌癌组织中MMP-2和TIMP-2蛋白表达的差异。结果经新辅助化疗后鳞癌与低分化癌MMP-2的下降与化疗前相比差异有显著性(P<0.01),而腺癌和中-高分化癌的下降与化疗前相比差异无显著性。结论鳞癌与低分化癌更适合新辅助化疗。
Objective To study the sensitivity of non-small cell lung cancer to neoadjuvant chemotherapy. Methods Immunohistochemical method was used to detect the difference of MMP-2 and TIMP-2 protein expression between non-small cell lung cancer and non-neoadjuvant chemotherapy group with different differentiation degree and pathological type. Results The decrease of MMP-2 in squamous cell carcinoma and poorly differentiated carcinoma after neoadjuvant chemotherapy was significantly different from that before chemotherapy (P <0.01), while the difference between adenocarcinoma and moderately-differentiated carcinoma was no significant difference compared with pre-chemotherapy Significance. Conclusion Squamous cell carcinoma and poorly differentiated carcinoma are more suitable for neoadjuvant chemotherapy.